US 12,325,881 B2
Method of determining and treating breast cancer
Siew Gek Lee-Lim, Singapore (SG); Ruiyang Zou, Singapore (SG); Lihan Zhou, Singapore (SG); He Cheng, Singapore (SG); Bo Anders Mikael Hartman, Singapore (SG); and Heng-Phon Too, Singapore (SG)
Assigned to AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Singapore (SG); Singapore Health Services Pte Ltd, Singapore (SG); National University Hospital (Singapore) Pte Ltd, Singapore (SG); Tan Tock Seng Hospital Pte Ltd, Singapore (SG); and Mirxes Lab Pte Ltd, Singapore (SG)
Filed by AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Singapore (SG); Singapore Health Services Pte Ltd, Singapore (SG); National University Hospital (Singapore) Pte Ltd, Singapore (SG); Tan Tock Seng Hospital Pte Ltd (TTSH), Singapore (SG); and MiRXES Lab Pte. Ltd., Singapore (SG)
Filed on Apr. 4, 2022, as Appl. No. 17/713,143.
Prior Publication US 2023/0313308 A1, Oct. 5, 2023
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 11 Claims
 
1. A method of diagnosing and treating breast cancer, the method comprising:
obtaining a bodily fluid sample from a human subject;
measuring the expression level of at least two or more miRNAs in the sample from the subject,
wherein the at least two miRNAs are miR-195-5p and miR-451a,
wherein, if present, more miRNAs are selected from the group consisting of miR-126-5p, miR-423-3p, miR-192-5p, and miR-17-5p,
wherein miR-195-5p and miR-451a are upregulated,
wherein, when measured, miR-126-5p is upregulated, and miR-423-3p, miR-192-5p, and miR-17-5p are unchanged,
wherein upregulated and/or unchanged expression levels of said miRNAs in the sample, as compared to miRNA expression levels in a cancer-free control, determines the subject to have breast cancer; and
treating the subject determined to have breast cancer with an anti-breast cancer compound.